What's new — Melanoma¶
Generated 2026-09-03 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a page; this says how recent the evidence on those pages is — so you can tell settled ground from a field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent¶
| Published within | Cited papers |
|---|---|
| last week | 0 |
| last month | 1 |
| last 2 months | 6 |
| last 3 months | 11 |
| last 6 months | 35 |
| last year | 61 |
| older than a year | 569 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first¶
The most recent cited papers, with the pages that use them.
| Published | Paper | Cited on |
|---|---|---|
| 2026-08-04 | A Multistep Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma — Cancer Res ([PMID 41661679](https://pubmed.ncbi.nlm.nih.gov/41661679/){target="_blank" rel="noopener"}) | uveal-melanoma |
| 2026-08-01 | [(99m)Tc]Tc-Tilmanocept sentinel node biopsy and long-term outcomes in melanoma: A cohort study and literature review — Eur J Surg Oncol ([PMID 42617582](https://pubmed.ncbi.nlm.nih.gov/42617582/){target="_blank" rel="noopener"}) | sentinel-node-and-nodal-management |
| 2026-08-01 | Systemic surveillance for uveal melanoma: Approach to optimization — PLoS One ([PMID 42616744](https://pubmed.ncbi.nlm.nih.gov/42616744/){target="_blank" rel="noopener"}) | uveal-melanoma |
| 2026-08-01 | Missed Opportunities for Neoadjuvant Immunotherapy in Melanoma: Is it Time to Consider Ultrasound Staging for Newly Diagnosed Patients? — Ann Surg Oncol ([PMID 42581274](https://pubmed.ncbi.nlm.nih.gov/42581274/){target="_blank" rel="noopener"}) | staging |
| 2026-08-01 | Population Skin Cancer Screening and Melanoma Mortality Rates — JAMA Dermatol ([PMID 42268621](https://pubmed.ncbi.nlm.nih.gov/42268621/){target="_blank" rel="noopener"}) | guidelines, overview, screening-and-overdiagnosis |
| 2026-07-15 | Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study — Cancer ([PMID 42411543](https://pubmed.ncbi.nlm.nih.gov/42411543/){target="_blank" rel="noopener"}) | adjuvant-therapy |
| 2026-07-02 | Efficacy, safety, and characteristics of adoptive tumor-infiltrating lymphocyte therapy in solid tumours: a systematic review and meta-analysis — Front Oncol ([PMID 42558559](https://pubmed.ncbi.nlm.nih.gov/42558559/){target="_blank" rel="noopener"}) | cellular-therapy-and-resistance |
| 2026-07-01 | Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries — CA Cancer J Clin ([PMID 42417444](https://pubmed.ncbi.nlm.nih.gov/42417444/){target="_blank" rel="noopener"}) | epidemiology-and-global-burden |
| 2026-07-01 | Impact of Multigene Panel Testing in High-Risk Uveal Melanoma Patients — Pigment Cell Melanoma Res ([PMID 42415513](https://pubmed.ncbi.nlm.nih.gov/42415513/){target="_blank" rel="noopener"}) | germline-predisposition, uveal-melanoma |
| 2026-07-01 | Immune checkpoint inhibitor-induced myasthenia gravis and myocarditis: a fatal immune-related adverse event — Immunol Res ([PMID 42384108](https://pubmed.ncbi.nlm.nih.gov/42384108/){target="_blank" rel="noopener"}) | red-flags-and-safety-concerns |
| 2026-07-01 | Prevalence of Familial Melanoma Genes and Cancer Risk Among Genomically Ascertained Individuals — JAMA Dermatol ([PMID 42201696](https://pubmed.ncbi.nlm.nih.gov/42201696/){target="_blank" rel="noopener"}) | germline-predisposition, red-flags-and-safety-concerns, special-populations, surveillance-and-survivorship |
| 2026-06-03 | Overdiagnosis of Melanoma In Situ — J Clin Med ([PMID 42279200](https://pubmed.ncbi.nlm.nih.gov/42279200/){target="_blank" rel="noopener"}) | red-flags-and-safety-concerns, screening-and-overdiagnosis |
| 2026-06-02 | Life-Threatening Secondary Adrenal Crisis Triggered by Pembrolizumab-Induced Hypophysitis: A Case Report — Cureus ([PMID 42528939](https://pubmed.ncbi.nlm.nih.gov/42528939/){target="_blank" rel="noopener"}) | red-flags-and-safety-concerns |
| 2026-06-02 | Implementing Paradigm Shifting Clinical Trials: Real-World Outcomes of Neoadjuvant Versus Adjuvant Immune Checkpoint Inhibitors in Advanced Melanoma Patients — Ann Surg Oncol ([PMID 42360644](https://pubmed.ncbi.nlm.nih.gov/42360644/){target="_blank" rel="noopener"}) | neoadjuvant-therapy |
| 2026-06-01 | Global patterns of melanoma, burden attributable to ultraviolet radiation exposure, and projections to 2050 across 185 countries: A population-based study with global modeling — JAAD Int ([PMID 42502459](https://pubmed.ncbi.nlm.nih.gov/42502459/){target="_blank" rel="noopener"}) | epidemiology-and-global-burden, risk-factors-and-prevention, screening-and-overdiagnosis |
| 2026-06-01 | Neoadjuvant Therapy and the Evolving Management of Resectable Advanced Melanoma — Cancers (Basel) ([PMID 42352510](https://pubmed.ncbi.nlm.nih.gov/42352510/){target="_blank" rel="noopener"}) | neoadjuvant-therapy |
| 2026-06-01 | Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study — J Clin Oncol ([PMID 42223134](https://pubmed.ncbi.nlm.nih.gov/42223134/){target="_blank" rel="noopener"}) | cellular-therapy-and-resistance, clinical-trials-landscape |
| 2026-05-26 | Understanding acral lentiginous melanoma: from the clinic to guidelines — Clin Exp Dermatol ([PMID 41219165](https://pubmed.ncbi.nlm.nih.gov/41219165/){target="_blank" rel="noopener"}) | acral-and-mucosal-melanoma |
| 2026-05-08 | Indirect Comparison of the Efficacy of Pembrolizumab Versus Nivolumab as Adjuvant Options for Stage IIB/IIC Melanoma — Target Oncol ([PMID 42101794](https://pubmed.ncbi.nlm.nih.gov/42101794/){target="_blank" rel="noopener"}) | adjuvant-therapy |
| 2026-05-02 | Immune Checkpoint Inhibitor-Induced Hypophysitis Presenting as Severe Hyponatremia: A Nephrology Perspective on Avoiding the Syndrome of Inappropriate Antidiuretic Hormone (SIADH) Pitfall — Cureus ([PMID 42359175](https://pubmed.ncbi.nlm.nih.gov/42359175/){target="_blank" rel="noopener"}) | red-flags-and-safety-concerns |
| 2026-05-02 | Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial — Nat Commun ([PMID 42168180](https://pubmed.ncbi.nlm.nih.gov/42168180/){target="_blank" rel="noopener"}) | clinical-trials-landscape, surveillance-and-survivorship |
| 2026-05-02 | A MAFG~MITF complex drives melanoma phenotype switching and progression — Nat Commun ([PMID 42168173](https://pubmed.ncbi.nlm.nih.gov/42168173/){target="_blank" rel="noopener"}) | cellular-therapy-and-resistance, targeted-therapy |
| 2026-05-01 | Five-year survival with tebentafusp in metastatic uveal melanoma — Ann Oncol ([PMID 42162665](https://pubmed.ncbi.nlm.nih.gov/42162665/){target="_blank" rel="noopener"}) | immunotherapy-advanced-disease, surveillance-and-survivorship, uveal-melanoma |
| 2026-05-01 | Sentinel lymph node detection in melanoma: indocyanine green fluorescence compared with conventional mapping techniques — Melanoma Res ([PMID 42108206](https://pubmed.ncbi.nlm.nih.gov/42108206/){target="_blank" rel="noopener"}) | sentinel-node-and-nodal-management |
| 2026-05-01 | Comparison of Disease Progression Between Amelanotic Melanoma and Melanotic Melanoma — Pigment Cell Melanoma Res ([PMID 42087524](https://pubmed.ncbi.nlm.nih.gov/42087524/){target="_blank" rel="noopener"}) | clinical-diagnosis-and-dermoscopy |
| 2026-04-17 | Melanoma of unknown primary shows an oncogenic pattern and clinical course of sun-exposed melanoma — Br J Dermatol ([PMID 41719057](https://pubmed.ncbi.nlm.nih.gov/41719057/){target="_blank" rel="noopener"}) | special-populations |
| 2026-04-02 | Immunoembolization in liver-predominant metastatic uveal melanoma: a single-center retrospective analysis — Front Oncol ([PMID 42109660](https://pubmed.ncbi.nlm.nih.gov/42109660/){target="_blank" rel="noopener"}) | uveal-melanoma |
| 2026-04-02 | Estimated cost-effectiveness of adjuvant nivolumab for resected stage IIB-IIC melanoma in the United States — Expert Rev Pharmacoecon Outcomes Res ([PMID 42033368](https://pubmed.ncbi.nlm.nih.gov/42033368/){target="_blank" rel="noopener"}) | adjuvant-therapy |
| 2026-04-02 | Uveal melanoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up — ESMO Open ([PMID 42020098](https://pubmed.ncbi.nlm.nih.gov/42020098/){target="_blank" rel="noopener"}) | guidelines |
| 2026-04-02 | Cancer in Pregnancy: Therapeutic Decisions at the Intersection of Two Lives — Diagnostics (Basel) ([PMID 41975782](https://pubmed.ncbi.nlm.nih.gov/41975782/){target="_blank" rel="noopener"}) | special-populations |
| 2026-04-02 | Age-specific melanoma incidence trends in Canada — Cancer Epidemiol ([PMID 41932245](https://pubmed.ncbi.nlm.nih.gov/41932245/){target="_blank" rel="noopener"}) | epidemiology-and-global-burden, special-populations |
| 2026-04-01 | Neoadjuvant systemic therapy in stage III and IV resectable melanoma: an update to management and future directions — N Z Med J ([PMID 41990381](https://pubmed.ncbi.nlm.nih.gov/41990381/){target="_blank" rel="noopener"}) | neoadjuvant-therapy |
| 2026-03-09 | Prognostic Implications of Primary Site in Cutaneous Head and Neck Melanoma After the Implementation of Sentinel Node Biopsy: A SEER-Based Analysis (2011-2020) — Ann Surg Oncol ([PMID 41803580](https://pubmed.ncbi.nlm.nih.gov/41803580/){target="_blank" rel="noopener"}) | brain-metastases, clinical-diagnosis-and-dermoscopy, red-flags-and-safety-concerns, sentinel-node-and-nodal-management |
| 2026-03-06 | [Immunohistochemistry of melanocytic tumours] — Pathologie (Heidelb) ([PMID 41790207](https://pubmed.ncbi.nlm.nih.gov/41790207/){target="_blank" rel="noopener"}) | histopathology-and-prognostic-factors |
| 2026-03-05 | Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study — Eur Heart J ([PMID 40884033](https://pubmed.ncbi.nlm.nih.gov/40884033/){target="_blank" rel="noopener"}) | immune-related-adverse-events, red-flags-and-safety-concerns |
| 2026-03-02 | Real-world management and outcomes of immune-mediated diarrhea and colitis: gaps in guideline adherence and opportunities for implementation — Support Care Cancer ([PMID 41902969](https://pubmed.ncbi.nlm.nih.gov/41902969/){target="_blank" rel="noopener"}) | red-flags-and-safety-concerns |
| 2026-03-02 | Sentinel Lymph Node Biopsy for Desmoplastic Melanoma: A Systematic Review and Meta-analysis — Ann Surg Oncol ([PMID 41870859](https://pubmed.ncbi.nlm.nih.gov/41870859/){target="_blank" rel="noopener"}) | histopathology-and-prognostic-factors, sentinel-node-and-nodal-management, staging |
| 2026-03-02 | Impact on Quality of Life and Psychological Dimensions in Caregivers of Melanoma and Sarcoma Patients: A Scoping Review — Cancers (Basel) ([PMID 41827744](https://pubmed.ncbi.nlm.nih.gov/41827744/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2026-03-01 | Translating ctDNA into cutaneous melanoma care: An international expert survey — Eur J Cancer ([PMID 41932032](https://pubmed.ncbi.nlm.nih.gov/41932032/){target="_blank" rel="noopener"}) | surveillance-and-survivorship |
| 2026-03-01 | BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations — Mol Biomed ([PMID 41807883](https://pubmed.ncbi.nlm.nih.gov/41807883/){target="_blank" rel="noopener"}) | targeted-therapy |
| 2026-03-01 | Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trial — Lancet Oncol ([PMID 41785896](https://pubmed.ncbi.nlm.nih.gov/41785896/){target="_blank" rel="noopener"}) | clinical-trials-landscape, uveal-melanoma |
| 2026-02-02 | When two lives intersect: melanoma in pregnancy: mechanisms, risks, and management strategies — Contemp Oncol (Pozn) ([PMID 42089033](https://pubmed.ncbi.nlm.nih.gov/42089033/){target="_blank" rel="noopener"}) | special-populations |
| 2026-02-02 | Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma: A Secondary Analysis of a Randomized Clinical Trial — JAMA Netw Open ([PMID 41701495](https://pubmed.ncbi.nlm.nih.gov/41701495/){target="_blank" rel="noopener"}) | adjuvant-therapy |
| 2026-01-01 | Cancer statistics, 2026 — CA Cancer J Clin ([PMID 41528114](https://pubmed.ncbi.nlm.nih.gov/41528114/){target="_blank" rel="noopener"}) | epidemiology-and-global-burden, overview, staging |
| 2026-01-01 | Surgical Excision Margins in Skin Melanomas with Breslow Thickness Greater than 2 mm: A Systematic Review and Meta-Analysis — Curr Pharm Des ([PMID 40108923](https://pubmed.ncbi.nlm.nih.gov/40108923/){target="_blank" rel="noopener"}) | surgical-management-and-margins |
| 2025-12-27 | Real-world outcomes of immune checkpoint inhibitors in people with HIV and skin cancer: a multicentre study — Oncologist ([PMID 41396687](https://pubmed.ncbi.nlm.nih.gov/41396687/){target="_blank" rel="noopener"}) | special-populations |
| 2025-12-03 | Immune signature-based uncoupling of checkpoint inhibitor efficacy and toxicity — Immunity ([PMID 41478279](https://pubmed.ncbi.nlm.nih.gov/41478279/){target="_blank" rel="noopener"}) | neoadjuvant-therapy |
| 2025-12-02 | Immunotherapy for Melanoma in Patients with Altered Immune Systems: Unique Challenges and Clinical Considerations — Adv Ther ([PMID 41461997](https://pubmed.ncbi.nlm.nih.gov/41461997/){target="_blank" rel="noopener"}) | special-populations |
| 2025-12-02 | A protocol for development of a microsimulation model platform to evaluate the potential benefits, harms, and cost-effectiveness of risk-tailored melanoma screening — PLoS One ([PMID 41452872](https://pubmed.ncbi.nlm.nih.gov/41452872/){target="_blank" rel="noopener"}) | screening-and-overdiagnosis |
| 2025-12-01 | Global Burden and Trends of Cutaneous Malignant Melanoma in the Elderly Population: Analysis of Global Burden of Disease Study 2021 — Clin Cosmet Investig Dermatol ([PMID 41425115](https://pubmed.ncbi.nlm.nih.gov/41425115/){target="_blank" rel="noopener"}) | epidemiology-and-global-burden |
| 2025-12-01 | A BRN2:MYC transcriptional axis regulates interconversion between therapy-resistant and tumorigenic phenotypes in melanoma — Cell Rep ([PMID 41405996](https://pubmed.ncbi.nlm.nih.gov/41405996/){target="_blank" rel="noopener"}) | cellular-therapy-and-resistance, targeted-therapy |
| 2025-12-01 | Artificial Intelligence-Detected Tumor-Infiltrating Lymphocytes and Outcomes in Anti-PD-1-Based Treated Melanoma — JAMA Oncol ([PMID 41100131](https://pubmed.ncbi.nlm.nih.gov/41100131/){target="_blank" rel="noopener"}) | histopathology-and-prognostic-factors, immunotherapy-advanced-disease |
| 2025-11-06 | Immune checkpoint inhibitor-induced toxicity: a real-world analysis of the role of BMI — Front Oncol ([PMID 41278286](https://pubmed.ncbi.nlm.nih.gov/41278286/){target="_blank" rel="noopener"}) | immune-related-adverse-events |
| 2025-11-06 | [How do doctors communicate results of genomic testing and its prognostic impact on uveal melanoma patients? Results of a qualitative study] — Bull Cancer ([PMID 41203514](https://pubmed.ncbi.nlm.nih.gov/41203514/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2025-11-06 | Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure — ESMO Open ([PMID 41202502](https://pubmed.ncbi.nlm.nih.gov/41202502/){target="_blank" rel="noopener"}) | cellular-therapy-and-resistance, immunotherapy-advanced-disease |
| 2025-11-04 | Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort — Ann Oncol ([PMID 41469296](https://pubmed.ncbi.nlm.nih.gov/41469296/){target="_blank" rel="noopener"}) | neoadjuvant-therapy |
| 2025-11-02 | A composite score of serum cytokines enables early identification of patients at high risk for irAEs under immune checkpoint inhibition — Front Immunol ([PMID 41394871](https://pubmed.ncbi.nlm.nih.gov/41394871/){target="_blank" rel="noopener"}) | immune-related-adverse-events |
| 2025-11-02 | Foot Melanoma Reconstruction Using a Refined Perforator Flap: Safety, Function, and Subregional Surgical Strategy — Plast Reconstr Surg ([PMID 41294367](https://pubmed.ncbi.nlm.nih.gov/41294367/){target="_blank" rel="noopener"}) | acral-and-mucosal-melanoma |
| 2025-10-08 | Real-World Efficacy and Safety of MEK Inhibitor for Patients With Advanced NRAS-Mutant Melanoma: A Single-Center Retrospective Study in Japan — J Dermatol ([PMID 41059590](https://pubmed.ncbi.nlm.nih.gov/41059590/){target="_blank" rel="noopener"}) | targeted-therapy |
| 2025-10-01 | Safety of immunotherapy after liver transplantation-A multicenter study of a prospective standardized clinical practice protocol — Liver Transpl ([PMID 41082711](https://pubmed.ncbi.nlm.nih.gov/41082711/){target="_blank" rel="noopener"}) | special-populations |
Trials — what has moved¶
63 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity | Trials |
|---|---|
| trial records updated in the last week | 1 |
| trial records updated in the last month | 7 |
| trial records updated in the last 2 months | 11 |
| trial records updated in the last 3 months | 15 |
| trial records updated in the last 6 months | 24 |
| trial records updated in the last year | 38 |
Recently updated registrations¶
Posted efficacy and safety results¶
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
| Results posted | Trial | Phase | N | Primary outcome | Serious AE | Other AE | Deaths |
|---|---|---|---|---|---|---|---|
| 2026-08-26 | A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination | PHASE3 | 579 | Adjusted Time-Averaged Nivolumab Serum Concentration Over the First 28 | 283 | 503 | 143 |
| 2024-04-05 | Neoadjuvant and Adjuvant Checkpoint Blockade | PHASE2 | 53 | Arm C: Number of Participants With the Pathologic Response Rate | 0 | 34 | 0 |
| 2023-11-21 | A Study to Compare the Administration of Pembrolizumab After Surgery V | PHASE2 | 313 | Two-Year Event-Free Survival Rate | 67 | 280 | 36 |
| 2023-07-27 | Effectiveness Study of Nivolumab Compared to Placebo in Prevention of | PHASE3 | 790 | Recurrence Free Survival (RFS) | 137 | 678 | 24 |
| 2022-06-24 | Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected H | PHASE3 | 976 | Recurrence-free Survival (RFS) | 198 | 807 | 38 |
| 2022-03-29 | A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Partici | PHASE2, PHASE3 | 714 | Progression Free Survival (PFS) | 295 | 612 | 227 |
| 2021-10-05 | An Investigational Immuno-therapy Study to Evaluate Safety and Effecti | PHASE2 | 119 | Intracranial Clinical Benefit Rate (CBR) | 64 | 115 | 39 |
| 2021-03-05 | Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratif | PHASE2 | 2 | Change in Activated GZMB+ CD8+T-cell Density Intratumorally, of Two Im | 1 | 2 | 0 |
| 2019-01-04 | Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resecti | PHASE3 | 1019 | Part 1: Percentage of Participants With Recurrence-Free Survival (RFS) | 210 | 852 | 60 |
| 2017-12-18 | A Study of Vemurafenib in Participants With Metastatic Melanoma | PHASE3 | 3219 | Percentage of Participants Experiencing Any Grade 3 or 4 Adverse Event | 1114 | 2956 | 0 |
| 2017-09-26 | Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimu | PHASE3 | 945 | Progression Free Survival (PFS) | 641 | 906 | 608 |
53 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence¶
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you have been away.
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate. Use this to find movement, not to rank evidence. See open questions for what remains unresolved, and the curation log for when these pages were last revised.